In the same in vivo model, they also demonstrated that Mir-211 overexpression confers resistance to vemurafenib (BRAFi) and cobimetinib (MEKi) through the activation of ERK5, a MAPK supporting melanoma growth [139], suggesting that DUSP6 may potentially prevent this undesirable effect [52]. The gene discussed is DUSP6; the disease is melanoma.